ALNYNasdaqPharmaceutical PreparationsFiscal year ends December 31
ALNYLAM PHARMACEUTICALS, INC.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Jul 30, 2026
$233.29+1.46 (+0.63%)
Close on Oct 19, 2026
- Market cap
- $32.26B
- P/E (TTM)
- 43.4
- Dividend yield
- –
Ownership
Institutional holdings as of Jun 30, 2026, from 13F filings
Held by institutions
99.8%
133M of 134M shares
Institutional holders
788
87 new, 80 sold out
Net institutional buying
2M
In Q2 2026
Insider trades, 12 months
0 buys · 278 sales
Net sold $43.56M
Shares held by institutions
Holders of more than 5%
Latest Schedule 13D (active) or 13G (passive) filed by each holder
| Holder | Shares | % of class | Filing | As of |
|---|---|---|---|---|
| Capital Research Global Investors | 9,471,181 | 7.10% | 13G (passive) amendment | Mar 31, 2026 |
| BlackRock, Inc. | 8,546,557 | 6.80% | 13G (passive) amendment | Dec 31, 2023 |
| Vanguard Capital Management | 7,104,536 | 5.35% | 13G (passive) | Mar 31, 2026 |
| Abigail P. Johnson | 16,834,095 | 12.80% | 13G (passive) amendment | Sep 30, 2025 |
| FMR LLC | 14,640,525 | 11.00% | 13G (passive) amendment | Mar 31, 2026 |
| Capital World Investors | 10,916,799 | 8.20% | 13G (passive) amendment | Mar 31, 2026 |
Top institutional holders
13F holdings as of Jun 30, 2026
| Holder | Shares | % of ALNY | Value | Change | % of portfolio |
|---|---|---|---|---|---|
| FMR LLC | 15,023,962 | 11.23% | $4.52B | +444,796 | 0.20% |
| Capital World Investors | 11,144,846 | 8.33% | $3.35B | +342,498 | 0.40% |
| BlackRock, Inc. | 10,907,675 | 8.15% | $3.28B | +462,767 | 0.05% |
| Capital Research Global Investors | 9,750,699 | 7.29% | $2.94B | +279,518 | 0.41% |
| Vanguard Portfolio Management LLC | 6,538,390 | 4.89% | $1.97B | +47,110 | 0.09% |
| Vanguard Capital Management LLC | 6,029,478 | 4.51% | $1.82B | +82,772 | 0.04% |
| T. Rowe Price Investment Management, Inc. | 5,642,173 | 4.22% | $1.70M | +448,849 | 1.11% |
| Invesco Ltd. | 3,754,318 | 2.81% | $1.13B | −320,802 | 0.09% |
| State Street Corp | 3,555,689 | 2.66% | $1.07B | +232,991 | 0.03% |
| JPMorgan Chase & Co | 2,675,517 | 2.00% | $785.32M | −3,648,235 | 0.04% |
| Geode Capital Management, LLC | 2,635,840 | 1.97% | $791.35M | −24,545 | 0.04% |
| Baillie Gifford & Co | 2,439,889 | 1.82% | $734.48M | −53,977 | 0.67% |
| Norges Bank | 2,271,813 | 1.70% | $683.88M | New | 0.07% |
| Wellington Management Group Llp | 2,110,407 | 1.58% | $635.30M | +174,482 | 0.11% |
| Orbis Allan Gray Ltd | 1,987,407 | 1.49% | $598.27M | +652,582 | 2.06% |
| Dodge & Cox | 1,955,393 | 1.46% | $588.63M | +26,140 | 0.31% |
| Two Sigma Investments, LP | 1,875,937 | 1.40% | $564.71M | −116,640 | 0.41% |
| American Century Companies Inc | 1,853,956 | 1.39% | $558.10M | +51,593 | 0.25% |
| Clearbridge Investments, LLC | 1,259,483 | 0.94% | $379.14M | −96,553 | 0.31% |
| Price T Rowe Associates Inc /Md/ | 1,149,201 | 0.86% | $345.95K | −283,547 | 0.03% |
Institutional buying and selling by quarter
Positions opened, added to, reduced and closed by 13F filers
| Quarter | Holders | Shares held | % of shares | New / added | Reduced / closed | Shares bought | Shares sold |
|---|---|---|---|---|---|---|---|
| Q2 2026 | 788 | 133M | 99.8% | 87 / 324 | 280 / 80 | 12M | 9M |
| Q1 2026 | 793 | 131M | 98.2% | 106 / 320 | 261 / 156 | 30M | 19M |
| Q4 2025 | 852 | 134M | 100.0% | 172 / 289 | 292 / 117 | 15M | 15M |
| Q3 2025 | 823 | 134M | 100.0% | 225 / 283 | 223 / 49 | 20M | 18M |
| Q2 2025 | 654 | 133M | 99.1% | 98 / 261 | 216 / 63 | 10M | 7M |
| Q1 2025 | 625 | 129M | 96.8% | 106 / 235 | 205 / 67 | 10M | 8M |
| Q4 2024 | 594 | 128M | 95.6% | 98 / 239 | 180 / 62 | 13M | 11M |
| Q3 2024 | 568 | 126M | 94.2% | 107 / 221 | 171 / 57 | 22M | 9M |
| Q2 2024 | 523 | 122M | 91.0% | 88 / 193 | 168 / 57 | 12M | 8M |
| Q1 2024 | 498 | 118M | 88.1% | 71 / 205 | 150 / 64 | 10M | 13M |
| Q4 2023 | 499 | 121M | 90.5% | 96 / 168 | 159 / 44 | 9M | 6M |
| Q3 2023 | 453 | 118M | 88.1% | 43 / 161 | 166 / 59 | 5M | 5M |
Top mutual fund and ETF holders
Latest monthly portfolio reports (Form N-PORT)
| Fund | Shares | % of ALNY | Value | % of fund | As of |
|---|---|---|---|---|---|
| Growth Fund of America | 7,670,994 | 5.73% | $2.32B | 0.64% | May 31, 2026 |
| Vanguard Total Stock Market Index Fund | 4,239,087 | 3.17% | $1.28B | 0.06% | Jun 30, 2026 |
| AMCAP Fund | 4,101,680 | 3.07% | $1.24B | 1.27% | May 31, 2026 |
| Vanguard Mid-Cap Index Fund | 2,893,030 | 2.16% | $870.89M | 0.39% | Jun 30, 2026 |
| Invesco QQQ Trust, Series 1 | 2,834,095 | 2.12% | $853.15M | 0.17% | Jun 30, 2026 |
| Fidelity OTC Portfolio | 2,140,824 | 1.60% | $439.98M | 1.02% | Jul 31, 2026 |
| Vanguard Health Care Fund | 2,136,580 | 1.60% | $439.11M | 1.15% | Jul 31, 2026 |
| T. Rowe Price Capital Appreciation Fund | 2,034,761 | 1.52% | $612.52M | 0.87% | Jun 30, 2026 |
| Vanguard Growth Index Fund | 1,624,001 | 1.21% | $488.87M | 0.13% | Jun 30, 2026 |
| Investment Co of America | 1,612,942 | 1.21% | $485.54M | 0.26% | Jun 30, 2026 |
| Vanguard Extended Market Index Fund | 1,530,865 | 1.14% | $460.84M | 0.47% | Jun 30, 2026 |
| Fidelity Growth Company Fund | 1,338,874 | 1.00% | $404.31M | 0.41% | May 31, 2026 |
| Dodge & Cox Stock Fund | 1,233,200 | 0.92% | $371.23M | 0.31% | Jun 30, 2026 |
| Growth Fund | 1,197,876 | 0.90% | $360.60M | 0.63% | Jun 30, 2026 |
| T. Rowe Price Mid-Cap Growth Fund, Inc. | 1,165,773 | 0.87% | $350.93M | 1.52% | Jun 30, 2026 |
Officers, directors and major owners
People who filed Forms 3, 4 or 5 in the last two years
| Name | Role | Shares owned | % of shares | Latest filing |
|---|---|---|---|---|
| Yvonne Greenstreet | Chief Executive Officer, Director | 96,209 | 0.07% | Sep 22, 2026 |
| Melissa McLaughlin | Chief Human Resources Officer | 11,673 | 0.01% | Apr 7, 2026 |
| Tolga Tanguler | EVP, Chief Commercial Officer | 34,297 | 0.03% | Mar 6, 2026 |
| Kevin Joseph Fitzgerald | CSO & EVP, Head of Research | 21,106 | 0.02% | Mar 6, 2026 |
| Jeffrey V. Poulton | EVP, Chief Financial Officer | 63,194 | 0.05% | Mar 6, 2026 |
| Pushkal Garg | EVP Chief R&D | 21,124 | 0.02% | Mar 6, 2026 |
| Bryan Supran | EVP, CLO and Secretary | 14,565 | 0.01% | Mar 4, 2026 |
| Robert W. Hesslein | EVP, CLO and Secretary | 8,002 | 0.01% | Mar 5, 2025 |
| Benjamin Cravatt | Director | – | – | Jun 3, 2026 |
| David E. I. Pyott | Director | 29,994 | 0.02% | Jun 3, 2026 |
| Dennis A. Ausiello | Director | 5,082 | 0.00% | May 22, 2026 |
| Peter N. Kellogg | Director | 1,446 | 0.00% | May 22, 2026 |
| Margaret A. Hamburg | Director | 1,582 | 0.00% | May 22, 2026 |
| Amy W. Schulman | Director | 24,049 | 0.02% | May 22, 2026 |
| Olivier Brandicourt | Director | 1,446 | 0.00% | May 22, 2026 |
| Stuart A. Arbuckle | Director | 671 | 0.00% | May 22, 2026 |
| Charles Elliott Sigal | Director | 3,446 | 0.00% | May 22, 2026 |
| Colleen F. Reitan | Director | 1,446 | 0.00% | May 22, 2026 |
| Michael W. Bonney | Director | 32,054 | 0.02% | Aug 19, 2025 |
| Carolyn R. Bertozzi | Director | 775 | 0.00% | May 12, 2025 |
| Phillip A. Sharp | Director | 278,149 | 0.21% | Jan 24, 2025 |
Insider trades
Common stock transactions reported on Form 4, newest first
| Insider | Date | Transaction | Shares | Price | Value | Shares after |
|---|---|---|---|---|---|---|
| Yvonne Greenstreet Chief Executive Officer, Director | Sep 19, 2026 | Award | +107 | – | – | 95,802 |
| David E. I. Pyott Director | Jun 1, 2026 | Sale(10b5-1 plan) | −1,222 | $299.87 | $366.44K | 2,094 |
| David E. I. Pyott Director | Jun 1, 2026 | Option exercise | +3,830 | – | – | 5,412 |
| David E. I. Pyott Director | Jun 1, 2026 | Sale(10b5-1 plan) | −495 | $300.72 | $148.86K | 1,599 |
| David E. I. Pyott Director | Jun 1, 2026 | Sale(10b5-1 plan) | −921 | $297.71 | $274.19K | 4,491 |
| David E. I. Pyott Director | Jun 1, 2026 | Sale(10b5-1 plan) | −17 | $302.65 | $5.15K | 1,582 |
| David E. I. Pyott Director | Jun 1, 2026 | Sale(10b5-1 plan) | −1,175 | $298.91 | $351.22K | 3,316 |
| David E. I. Pyott Director | May 20, 2026 | Award | +671 | – | – | 1,582 |
| Dennis A. Ausiello Director | May 20, 2026 | Award | +671 | – | – | 1,582 |
| Charles Elliott Sigal Director | May 20, 2026 | Award | +671 | – | – | 1,446 |
| Peter N. Kellogg Director | May 20, 2026 | Award | +671 | – | – | 1,446 |
| Colleen F. Reitan Director | May 20, 2026 | Award | +671 | – | – | 1,446 |
| Olivier Brandicourt Director | May 20, 2026 | Award | +671 | – | – | 1,446 |
| Amy W. Schulman Director | May 20, 2026 | Award | +838 | – | – | 24,049 |
| Stuart A. Arbuckle Director | May 20, 2026 | Award | +671 | – | – | 671 |
| Margaret A. Hamburg Director | May 20, 2026 | Award | +671 | – | – | 1,582 |
| Amy W. Schulman Director | May 13, 2026 | Option exercise | +11,250 | $70.20 | $789.75K | 23,211 |
| Melissa McLaughlin Chief Human Resources Officer | Apr 6, 2026 | Sale(10b5-1 plan) | −56 | $320.14 | $17.93K | 11,673 |
| Melissa McLaughlin Chief Human Resources Officer | Apr 6, 2026 | Sale(10b5-1 plan) | −909 | $329.76 | $299.75K | 10,764 |
| Melissa McLaughlin Chief Human Resources Officer | Apr 6, 2026 | Sale(10b5-1 plan) | −829 | $330.46 | $273.95K | 9,935 |
| Melissa McLaughlin Chief Human Resources Officer | Apr 6, 2026 | Sale(10b5-1 plan) | −293 | $331.89 | $97.24K | 9,642 |
| Melissa McLaughlin Chief Human Resources Officer | Apr 6, 2026 | Sale(10b5-1 plan) | −199 | $333.94 | $66.45K | 9,443 |
| Melissa McLaughlin Chief Human Resources Officer | Apr 2, 2026 | Sale(10b5-1 plan) | −147 | $320.62 | $47.13K | 12,287 |
| Melissa McLaughlin Chief Human Resources Officer | Apr 2, 2026 | Sale(10b5-1 plan) | −245 | $322.86 | $79.10K | 11,818 |
| Melissa McLaughlin Chief Human Resources Officer | Apr 2, 2026 | Sale(10b5-1 plan) | −224 | $321.64 | $72.05K | 12,063 |
| Melissa McLaughlin Chief Human Resources Officer | Apr 2, 2026 | Sale(10b5-1 plan) | −86 | $319.69 | $27.49K | 12,434 |
| Melissa McLaughlin Chief Human Resources Officer | Apr 2, 2026 | Sale(10b5-1 plan) | −81 | $323.64 | $26.21K | 11,737 |
| Melissa McLaughlin Chief Human Resources Officer | Apr 2, 2026 | Sale(10b5-1 plan) | −8 | $325.49 | $2.60K | 11,729 |
| Melissa McLaughlin Chief Human Resources Officer | Apr 2, 2026 | Sale(10b5-1 plan) | −359 | $317.44 | $113.96K | 12,729 |
| Melissa McLaughlin Chief Human Resources Officer | Apr 2, 2026 | Sale(10b5-1 plan) | −265 | $316.61 | $83.90K | 13,088 |
| Melissa McLaughlin Chief Human Resources Officer | Apr 2, 2026 | Sale(10b5-1 plan) | −209 | $318.47 | $66.56K | 12,520 |
| Kevin Joseph Fitzgerald CSO & EVP, Head of Research | Mar 5, 2026 | Sale(10b5-1 plan) | −153 | $326.24 | $49.91K | 20,569 |
| Kevin Joseph Fitzgerald CSO & EVP, Head of Research | Mar 5, 2026 | Sale(10b5-1 plan) | −148 | $324.60 | $48.04K | 20,722 |
| Kevin Joseph Fitzgerald CSO & EVP, Head of Research | Mar 5, 2026 | Sale(10b5-1 plan) | −233 | $323.25 | $75.32K | 20,870 |
| Kevin Joseph Fitzgerald CSO & EVP, Head of Research | Mar 5, 2026 | Sale(10b5-1 plan) | −124 | $321.81 | $39.90K | 21,103 |
| Pushkal Garg EVP Chief R&D | Mar 5, 2026 | Sale(10b5-1 plan) | −654 | $322.33 | $210.80K | 20,443 |
| Pushkal Garg EVP Chief R&D | Mar 5, 2026 | Sale(10b5-1 plan) | −740 | $323.55 | $239.43K | 19,703 |
| Pushkal Garg EVP Chief R&D | Mar 5, 2026 | Sale(10b5-1 plan) | −510 | $324.59 | $165.54K | 19,193 |
| Pushkal Garg EVP Chief R&D | Mar 5, 2026 | Sale(10b5-1 plan) | −500 | $326.08 | $163.04K | 18,693 |
| Kevin Joseph Fitzgerald CSO & EVP, Head of Research | Mar 4, 2026 | Sale(10b5-1 plan) | −59 | $320.81 | $18.93K | 21,744 |
| Kevin Joseph Fitzgerald CSO & EVP, Head of Research | Mar 4, 2026 | Sale(10b5-1 plan) | −79 | $321.82 | $25.42K | 21,665 |
| Kevin Joseph Fitzgerald CSO & EVP, Head of Research | Mar 4, 2026 | Sale(10b5-1 plan) | −28 | $320.01 | $8.96K | 21,803 |
| Kevin Joseph Fitzgerald CSO & EVP, Head of Research | Mar 4, 2026 | Sale(10b5-1 plan) | −57 | $325.67 | $18.56K | 21,227 |
| Kevin Joseph Fitzgerald CSO & EVP, Head of Research | Mar 4, 2026 | Sale(10b5-1 plan) | −75 | $324.88 | $24.37K | 21,284 |
| Kevin Joseph Fitzgerald CSO & EVP, Head of Research | Mar 4, 2026 | Sale(10b5-1 plan) | −210 | $323.84 | $68.01K | 21,359 |
| Kevin Joseph Fitzgerald CSO & EVP, Head of Research | Mar 4, 2026 | Sale(10b5-1 plan) | −96 | $323.01 | $31.01K | 21,569 |
| Kevin Joseph Fitzgerald CSO & EVP, Head of Research | Mar 4, 2026 | Sale(10b5-1 plan) | −29 | $319.03 | $9.25K | 21,831 |
| Jeffrey V. Poulton EVP, Chief Financial Officer | Mar 4, 2026 | Sale | −374 | $323.01 | $120.81K | 63,137 |
| Jeffrey V. Poulton EVP, Chief Financial Officer | Mar 4, 2026 | Sale | −309 | $321.82 | $99.44K | 63,511 |
| Jeffrey V. Poulton EVP, Chief Financial Officer | Mar 4, 2026 | Sale | −230 | $320.81 | $73.79K | 63,820 |
| Jeffrey V. Poulton EVP, Chief Financial Officer | Mar 4, 2026 | Sale | −291 | $324.88 | $94.54K | 62,028 |
| Jeffrey V. Poulton EVP, Chief Financial Officer | Mar 4, 2026 | Sale | −818 | $323.84 | $264.90K | 62,319 |
| Jeffrey V. Poulton EVP, Chief Financial Officer | Mar 4, 2026 | Sale | −223 | $325.67 | $72.62K | 61,805 |
| Jeffrey V. Poulton EVP, Chief Financial Officer | Mar 4, 2026 | Sale | −109 | $320.01 | $34.88K | 64,050 |
| Jeffrey V. Poulton EVP, Chief Financial Officer | Mar 4, 2026 | Sale | −114 | $319.03 | $36.37K | 64,159 |
| Yvonne Greenstreet Chief Executive Officer, Director | Mar 4, 2026 | Sale | −129 | $320.01 | $41.28K | 98,364 |
| Yvonne Greenstreet Chief Executive Officer, Director | Mar 4, 2026 | Sale | −345 | $324.88 | $112.08K | 95,960 |
| Yvonne Greenstreet Chief Executive Officer, Director | Mar 4, 2026 | Sale | −135 | $319.03 | $43.07K | 98,493 |
| Yvonne Greenstreet Chief Executive Officer, Director | Mar 4, 2026 | Sale | −265 | $325.67 | $86.30K | 95,695 |
| Yvonne Greenstreet Chief Executive Officer, Director | Mar 4, 2026 | Sale | −274 | $320.81 | $87.90K | 98,090 |
Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.
Planned insider sales
Notices of proposed sale filed on Form 144 before shares are sold
| Seller | Filed | Shares | Market value | Planned sale | Acquired through |
|---|---|---|---|---|---|
| Bryan Supran Officer | Oct 2, 2026 | 1,758 | $398.86K | Oct 2, 2026 | Restricted Stock Vesting |
| David E. I. Pyott Director | Jun 1, 2026 | 3,830 | $1.15M | Jun 1, 2026 | Exercise of stock options |
| Melissa McLaughlin Officer | Apr 6, 2026 | 2,286 | $731.75K | Apr 6, 2026 | Stock Award |
| Pushkal Garg Officer | Mar 5, 2026 | 2,404 | $778.15K | Mar 5, 2026 | RSU |
| Kevin Joseph Fitzgerald Officer | Mar 5, 2026 | 658 | $212.99K | Mar 5, 2026 | RSU |
| Kevin Joseph Fitzgerald Officer | Mar 3, 2026 | 1,652 | $530.90K | Mar 3, 2026 | RSU |
| Pushkal Garg Officer | Mar 3, 2026 | 1,775 | $570.43K | Mar 3, 2026 | RSU |
| Pushkal Garg Officer | Feb 27, 2026 | 4,627 | $1.53M | Feb 27, 2026 | PSU |
| Kevin Joseph Fitzgerald Officer | Feb 17, 2026 | 2,041 | $677.53K | Feb 17, 2026 | PSU |
| Kevin Joseph Fitzgerald Officer | Jan 13, 2026 | 2,290 | $845.24K | Jan 13, 2026 | PSU |
| Kevin Joseph Fitzgerald Officer | Nov 17, 2025 | 12,128 | $5.45M | Nov 17, 2025 | Exercise of stock options |
| Yvonne Greenstreet Officer, Director | Nov 12, 2025 | 25,650 | $11.62M | Nov 12, 2025 | Exercise of stock options |
| Pushkal Garg Officer | Oct 3, 2025 | 3,022 | $1.36M | Oct 3, 2025 | PSU |
| Colleen F. Reitan Director | Sep 9, 2025 | 18,000 | $8.30M | Sep 9, 2025 | Exercise of stock options |
| Tolga Tanguler Officer | Aug 29, 2025 | 3,474 | $1.57M | Aug 29, 2025 | PSU |